Display options
Cite
Quartuccio N, Salem A, Laudicella R, et al. The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. Nucl Med Commun. 2021;42(8):839-845doi: 10.1097/MNM.0000000000001407.
Quartuccio, N., Salem, A., Laudicella, R., Spataro, A., Chiaravalloti, A., Caobelli, F., Cistaro, A., Alongi, P., & Evangelista, L. (2021). The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. Nuclear medicine communications, 42(8), 839-845. https://doi.org/10.1097/MNM.0000000000001407
Quartuccio, Natale, et al. "The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review." Nuclear medicine communications vol. 42,8 (2021): 839-845. doi: https://doi.org/10.1097/MNM.0000000000001407
Quartuccio N, Salem A, Laudicella R, Spataro A, Chiaravalloti A, Caobelli F, Cistaro A, Alongi P, Evangelista L. The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. Nucl Med Commun. 2021 Aug 01;42(8):839-845. doi: 10.1097/MNM.0000000000001407. PMID: 33741854.
Copy Download .nbib Format: NLM
Share it on

Nucl Med Commun. 2021 Aug 01;42(8):839-845. doi: 10.1097/MNM.0000000000001407.

The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review.

Nuclear medicine communications

Natale Quartuccio, Ahmed Salem, Riccardo Laudicella, Alessandro Spataro, Agostino Chiaravalloti, Federico Caobelli, Angelina Cistaro, Pierpaolo Alongi, Laura Evangelista

Affiliations

  1. Nuclear Medicine Unit, ARNAS Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy.
  2. Division of Cancer Sciences, University of Manchester.
  3. Clinical Oncology Department, Christie NHS Foundation Trust, Manchester, UK.
  4. Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina.
  5. Department of Biomedicine and Prevention, University Tor Vergata, Rome.
  6. Nuclear Medicine Section, IRCCS Neuromed, Pozzilli, Italy.
  7. Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben, Basel, Switzerland.
  8. Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa.
  9. Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, Cefalù.
  10. Nuclear Medicine Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.

PMID: 33741854 DOI: 10.1097/MNM.0000000000001407

Abstract

AIM: 18F-Fluorodeoxyglucose (FDG) PET imaging may play an important role in the restaging of patients with small-cell lung cancer (SCLC),, nevertheless, a systematic review of literature was still missing in this setting. The aim of this review was to summarize the evidence on literature regarding the utility of 18F-FDG PET imaging in restaging patients with SCLC.

METHODS: A literature search was performed to retrieve original studies using 18F-FDG PET or 18F-FDG PET/computed tomography (CT) in a minimum of 10 patients with SCLC at restaging.

RESULTS: The selected literature (17 studies) was discussed in four sections: detection rate, impact on management, prediction of prognosis and evaluation of the response to therapy. According to the literature, PET imaging may result in discordance with conventional imaging, mainly contrast-enhanced CT (ceCT), and detect additional lesions in a certain proportion of cases, leading to upstaging or downstaging. A variable level of disagreement between PET and conventional imaging has been reported also in the evaluation of response to therapy. A positive PET study is associated with shorter survival, especially in the presence of distant metastases. According to some studies, semiquantitative parameters are also inversely associated with overall survival and progression-free survival. Although the retrieved articles proved the utility of 18F-FDG PET imaging in each clinical setting, literature is still limited.

CONCLUSIONS: This review encourages the use of 18F-FDG PET imaging, especially in conjunction with ceCT in recurrent SCLC patients. Further level I evidence is needed to further assess the diagnostic and prognostic capability of 18F-FDG PET/ceCT findings in SCLC.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. - PubMed
  2. Cistaro A, Quartuccio N, Mojtahedi A, Fania P, Filosso PL, Campenni A, et al. Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification. Radiol Oncol. 2013; 47:219–223. - PubMed
  3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24:4539–4544. - PubMed
  4. Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012; 4:617–620. - PubMed
  5. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al.; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018; 379:2220–2229. - PubMed
  6. Aupérin A, Arriagada R, Pignon J-P, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999; 341:476–484. - PubMed
  7. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al.; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017; 18:1116–1125. - PubMed
  8. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al.; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357:664–672. - PubMed
  9. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015; 385:36–42. - PubMed
  10. Kalemkerian GP, Schneider BJ. Advances in small cell lung cancer. Hematol Oncol Clin North Am. 2017; 31:143–156. - PubMed
  11. Quartuccio N, Evangelista L, Alongi P, Caobelli F, Altini C, Cistaro A, et al.; Young AIMN Working Group. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study. Nucl Med Commun. 2019; 40:808–814. - PubMed
  12. Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C. Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer: secondary analysis of a randomized clinical trial. JAMA Oncol. 2019; 5:e185335. - PubMed
  13. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, et al. NCCN Guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 2018; 16:1171–1182. - PubMed
  14. Kalemkerian GP. Small cell lung cancer. Semin Respir Crit Care Med. 2016; 37:783–796. - PubMed
  15. Manoharan P, Salem A, Mistry H, Gornall M, Harden S, Julyan P, et al. 18F-Fludeoxyglucose PET/CT in SCLC: analysis of the CONVERT randomized controlled trial. J Thorac Oncol. 2019; 14:1296–1305. - PubMed
  16. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009; 6:e1000097. - PubMed
  17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529–536. - PubMed
  18. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007; 30:45–50. - PubMed
  19. Zhao DS, Valdivia AY, Li Y, Blaufox MD. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med. 2002; 32:272–275. - PubMed
  20. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol. 2004; 27:164–171. - PubMed
  21. Shi P, Meng X, Ni M, Sun X, Xing L, Yu J. Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer. Oncol Lett. 2015; 10:3123–3128. - PubMed
  22. Gregory DL, Brennan SM, Stillie A, Herschtal A, Hicks RJ, MacManus MP, Ball DL. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer. J Med Imaging Radiat Oncol. 2010; 54:100–107. - PubMed
  23. Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, Ozguven MA. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011; 25:406–413. - PubMed
  24. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003; 44:1911–1917. - PubMed
  25. Kim H, Yoo IR, Boo SH, Park HL, O JH, Kim SH. Prognostic value of pre- and post-treatment FDG PET/CT parameters in small cell lung cancer patients. Nucl Med Mol Imaging. 2018; 52:31–38. - PubMed
  26. Onitilo AA, Engel JM, Demos JM, Mukesh B. Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res. 2008; 6:72–77. - PubMed
  27. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003; 30:78–84. - PubMed
  28. van Loon J, Offermann C, Ollers M, van Elmpt W, Vegt E, Rahmy A, et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol. 2011; 99:172–175. - PubMed
  29. Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging. 2013; 13:73–80. - PubMed
  30. Lee J, Kim JO, Jung CK, Kim YS, Yoo IeR, Choi WH, et al. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation. Clin Lung Cancer. 2014; 15:e13–e21. - PubMed
  31. Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, et al. The role of advanced imaging in assessing response to definitive chemoradiation before prophylactic cranial irradiation in limited-stage small-cell lung cancer. Clin Lung Cancer. 2018; 19:e205–e209. - PubMed
  32. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Daugaard G, et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer. 2006; 54:41–49. - PubMed
  33. Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y. Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol. 2009; 11:467–472. - PubMed
  34. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006; 33:13–21. - PubMed
  35. Martucci F, Pascale M, Valli MC, Pesce GA, Froesch P, Giovanella L, et al. Impact of 18F-FDG PET/CT in staging patients with small cell lung cancer: a systematic review and meta-analysis. Front Med (Lausanne). 2019; 6:336. - PubMed
  36. Lu YY, Chen JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014; 35:697–703. - PubMed
  37. Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging. 2012; 11:253–258. - PubMed
  38. Sager O, Dincoglan F, Demiral S, Uysal B, Gamsiz H, Elcim Y, et al. Utility of molecular imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose positron emission tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): a radiation oncology perspective. Curr Radiopharm. 2019; 12:4–10. - PubMed
  39. Hazelton TR, Coppage L. Imaging for lung cancer restaging. Semin Roentgenol. 2005; 40:182–192. - PubMed
  40. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, Ball DL. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001; 42:1605–1613. - PubMed

Substances

MeSH terms

Publication Types